MaxCyte’s Strong Performance and Growth Potential Justifies Buy Rating by Mark Massaro
BTIG analyst Mark Massaro reiterated a Buy rating on MaxCyte (MXCT – Research Report) yesterday and set a price target of $8.00. Mark ...
Immuno Cure Biotech Presents Promising Results On Phase I Clinical Trial Of A Therapeutic HIV DNA Vaccine Media Outreach Newswire APAC
HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...
Taiwan News17h
Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development ...